Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy and safety of the humanized
anti-human IL-6 receptor monoclonal antibody tocilizumab (TCZ) either in monotherapy or in
combination therapy with methotrexate (MTX) in patients with an inadequate response to
treatment with MTX.
Furthermore, in patients who have been able to achieve control of disease activity via the
above therapy, we investigate the possibility of stopping TCZ and verify safety when TCZ is
restarted after disease recurrence.